StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen tEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — U.S. product sales ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail

QuarterlyAnnual
Latest, Q2 2026
520
Period ended Jun 30, 2026
Change on a year earlier
+11.6%
466 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
9
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — U.S. product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026520+11.6%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026424+16.2%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 2025409-10.3%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 2025518+7.5%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 2025466-2.5%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 2025365-12.9%Form 10-Q (filed 2026-05-01) ↗
Q4 2024Dec 31, 2024456+3.4%Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 2024482–Form 10-Q (filed 2025-11-05) ↗
Q2 2024Jun 30, 2024478–Form 10-Q (filed 2025-08-06) ↗
Q1 2024Mar 31, 2024419–Form 10-Q (filed 2025-05-02) ↗
Q4 2023Dec 31, 2023441–Form 10-K (filed 2026-02-13) ↗
Q3 2023Sep 30, 20230–Form 10-Q (filed 2024-10-31) ↗
Q2 2023Jun 30, 20230–Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 20230–Form 10-Q (filed 2024-05-03) ↗

Cite this data

StockData. (2026). Amgen TEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — U.S. product sales ($M) ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_tepezza_us

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.